Denali Therapeutics Inc. (DNLI): Skating on Thin Ice? We Know the Answer

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp

Denali Therapeutics Inc. (NASDAQ:DNLI) went down by -9.94% from its latest closing price compared to the recent 1-year high of $93.94. The company’s stock price has collected -1.60% of loss in the last five trading sessions. Press Release reported on 02/25/21 that Denali Therapeutics Reports Full Year 2020 Financial Results and Business Highlights

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Is It Worth Investing in Denali Therapeutics Inc. (NASDAQ :DNLI) Right Now?

Denali Therapeutics Inc. (NASDAQ:DNLI) scored a price-to-earnings ratio above its average ratio, recording 254.27 x from its present earnings ratio. Opinions of the stock are interesting as 7 analysts out of 10 who provided ratings for Denali Therapeutics Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 3 rated it as “hold,” and 0 as “sell.”

The 2021 Backdoor Crypto Portfolio (free)

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.


The average price from analysts is $93.88, which is $14.12 above the current price. DNLI currently public float of 98.80M and currently shorts hold a 7.06% ratio of that float. Today, the average trading volume of DNLI was 678.04K shares.

DNLI’s Market Performance

DNLI stocks went down by -1.60% for the week, with a monthly drop of -8.75% and a quarterly performance of 6.66%, while its annual performance rate touched 227.06%. The volatility ratio for the week stands at 9.82% while the volatility levels for the past 30 days are set at 7.57% for Denali Therapeutics Inc.. The simple moving average for the period of the last 20 days is -5.39% for DNLI stocks with a simple moving average of 37.97% for the last 200 days.

Analysts’ Opinion of DNLI

Many brokerage firms have already submitted their reports for DNLI stocks, with H.C. Wainwright repeating the rating for DNLI by listing it as a “Buy.” The predicted price for DNLI in the upcoming period, according to H.C. Wainwright is $95 based on the research report published on February 26th of the current year 2021.

Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see DNLI reach a price target of $105. The rating they have provided for DNLI stocks is “Overweight” according to the report published on February 10th, 2021.

H.C. Wainwright gave a rating of “Buy” to DNLI, setting the target price at $80 in the report published on November 11th of the previous year.

DNLI Trading at -13.58% from the 50-Day Moving Average

After a stumble in the market that brought DNLI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -31.17% of loss for the given period.

Volatility was left at 7.57%, however, over the last 30 days, the volatility rate increased by 9.82%, as shares sank -5.61% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -21.04% lower at present.

During the last 5 trading sessions, DNLI fell by -1.60%, which changed the moving average for the period of 200-days by +173.75% in comparison to the 20-day moving average, which settled at $68.15. In addition, Denali Therapeutics Inc. saw -22.80% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at DNLI starting from Krognes Steve E., who sale 50,000 shares at the price of $65.09 back on Feb 16. After this action, Krognes Steve E. now owns 900,000 shares of Denali Therapeutics Inc., valued at $3,254,710 using the latest closing price.

BRATTON DOUGLAS K, the 10% Owner of Denali Therapeutics Inc., sale 2,216,798 shares at $65.00 during a trade that took place back on Feb 12, which means that BRATTON DOUGLAS K is holding 9,984,836 shares at $144,091,870 based on the most recent closing price.

Stock Fundamentals for DNLI

Current profitability levels for the company are sitting at:

  • +18.69 for the present operating margin

The net margin for Denali Therapeutics Inc. stands at +21.19. The total capital return value is set at 7.46, while invested capital returns managed to touch 8.48. Equity return is now at value -37.10, with -29.10 for asset returns.

Based on Denali Therapeutics Inc. (DNLI), the company’s capital structure generated 5.58 points at debt to equity in total, while total debt to capital is 5.28. Total debt to assets is 4.00, with long-term debt to equity ratio resting at 5.58. Finally, the long-term debt to capital ratio is 5.28.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

When we switch over and look at the enterprise to sales, we see a ratio of 23.94, with the company’s debt to enterprise value settled at 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 20.86.

Sign up for our FREE Newsletter and get:

Leave a Comment

Your email address will not be published. Required fields are marked *

Sign up for our FREE Newsletter and get:

Is Stereotaxis Inc. (STXS) a Keeper?

Stereotaxis Inc. (AMEX:STXS) went up by 0.36% from its latest closing price compared to the recent 1-year high of $8.57. The company’s stock price has

Get The Best Stocks To Trade Every Day!...100% Free

We do not sell or share your information with anyone.

Get The Best Stocks To Trade Every Day!

Join now to get the pre-market morning brief 100% free

We do not sell or share your information with anyone.

Get Best Morning Financial Newsletter... 100% Free

Best stocks ideas

Analysts’ Upgrades & Downgrades

Important Earnings

Insider Watchlist

We do not sell or share your information with anyone.